Filing Details
- Accession Number:
- 0000950170-24-124184
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-11-08 16:43:56
- Reporting Period:
- 2024-11-06
- Accepted Time:
- 2024-11-08 16:43:56
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1863127 | Tyra Biosciences Inc. | TYRA | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1381980 | S Nina Kjellson | C/O Tyra Biosciences, Inc. 2656 State Street Carlsbad CA 92008 | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2024-11-06 | 46,856 | $17.18 | 3,755,591 | No | 4 | S | Indirect | By Canaan XI L.P. |
| Common Stock | Disposition | 2024-11-06 | 5,635 | $17.18 | 451,629 | No | 4 | S | Indirect | By 2020+ Co-Investment L.P. - Series 7 |
| Common Stock | Disposition | 2024-11-07 | 19,720 | $17.32 | 3,735,871 | No | 4 | S | Indirect | By Canaan XI L.P. |
| Common Stock | Disposition | 2024-11-07 | 2,371 | $17.32 | 449,258 | No | 4 | S | Indirect | By 2020+ Co-Investment L.P. - Series 7 |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Indirect | By Canaan XI L.P. |
| No | 4 | S | Indirect | By 2020+ Co-Investment L.P. - Series 7 |
| No | 4 | S | Indirect | By Canaan XI L.P. |
| No | 4 | S | Indirect | By 2020+ Co-Investment L.P. - Series 7 |
Footnotes
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.75 to $17.75. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- The sole general partner of Canaan XI L.P. ("Canaan XI") is Canaan Partners XI LLC ("Canaan XI GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any.
- The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the "Canaan Series 7") is Canaan Partners 2020+ Co-Investment LLC ("Canaan 2020+ GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.00 to $17.67. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Billionaire Hedge Funds
